Stephen J. Freedland

Stephen J. Freedland

Urology

8635 W 3rd St Ste 1070W Ofc West
Los Angeles, CA 90048

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 815 publications

Local growth hormone promotes benign prostatic hyperplasia.

Local growth hormone promotes benign prostatic hyperplasia.

Journal: JCI insight

Published: July 28, 2026

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Journal: Future oncology (London, England)

Published: July 09, 2026

Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations.

Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations.

Journal: JCO clinical cancer informatics

Published: July 08, 2026

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Journal: Future oncology (London, England)

Published: July 06, 2026

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: July 02, 2026

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Journal: Future oncology (London, England)

Published: June 23, 2026

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Journal: Current medical research and opinion

Published: April 23, 2026

The effect of dutasteride on storage symptoms in men with lower urinary tract symptoms: a REDUCE trial analysis.

The effect of dutasteride on storage symptoms in men with lower urinary tract symptoms: a REDUCE trial analysis.

Journal: The aging male : the official journal of the International Society for the Study of the Aging Male

Published: April 21, 2026

Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.

Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.

Journal: European urology

Published: April 15, 2026

Patient Participation in Consultations for Clinically Localized Prostate Cancer: Erratum.

Patient Participation in Consultations for Clinically Localized Prostate Cancer: Erratum.

Journal: The Journal of urology

Published: April 09, 2026

Showing 1-12 of 815

Last Updated: 09/26/2026